Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Wednesday, March 19 based on AAII’s Stock Grades.

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the ...

Some Xbox players who recently wanted to get cracking into some video games might have turned their Xbox console on to see a welcome screen. A new update was recently released for those who joined ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European countries in January 2025 following the receipt of CE Mark Certification in November 2024.

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per share of ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...